Early heart attack drug could slash repeat cardiac events

NCT ID NCT07208006

Recruiting now Disease control Sponsor: Shanghai Zhongshan Hospital Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 20, 2026 · Updated 33 times

Summary

This study tests whether giving a PCSK9 inhibitor (a powerful cholesterol-lowering drug) very early in the hospital, along with standard care, can reduce the risk of major heart problems like death, another heart attack, or stroke over the next year. About 1,500 adults who recently had a heart attack and have blockages in multiple heart arteries will take part. The goal is to see if this early treatment helps stabilize dangerous plaques and improves outcomes.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYOCARDIAL INFARCTION (AMI) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Zhongshan Hospital, Fudan University
RECRUITING

Shanghai, Shanghai Municipality, 200032, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

ACUTE MYOCARDIAL INFARCTION (AMI)